The week of 4-8 November 2024 is set aside to celebrate the work of nearly 1 million trustees volunteering for charities across the UK. Trustees are individuals responsible for the
Breast cancer patients denied life-extending drug by NICE
A cancer drug which received standing ovation from the Global Medical Community is being withheld from NHS breast cancer patients. METUPUK are devastated by NICE decision not to recommend the drug
Emma Lawrence (née Fisher)
Emma Lawrence (née Fisher) 21.01.81 – 13.07.24 Everyone at METUPUK is incredibly saddened to hear that Emma Lawrence (née Fisher) has died at the age of 43. Emma was diagnosed
The Economist – Pioneering person-centred breast cancer care – Madeleine Meynell
At the End of May 2024 Madeleine attended an event at the offices of the Economist on Pioneering person-centred breast cancer care. This event was part of a wider project looking at
When D-Day’s DE NOVO – Sue Thomas
When D-Day’s DE NOVO My name is Sue, I’m a wife, a mum, a nanny, a daughter, a friend, a Metastatic Breast Cancer patient, and an advocate. My breast cancer
Tassia Haines
We are heartbroken to share the news that Tassia Haines has died. A member of METUPUK and our Executive Lead for Wales, Tass had been a significant campaigner for MBC
Emma Saville
We met Emma as she applied to be one of the METUPUK Darker Side of Pink ladies with our campaign that started in 2021 which focused on metastatic breast cancer,
The Irony of Metastatic Breast Cancer – Mary Huckle
Many of our followers on social media will remember Mary Huckle and her tireless campaigning for #metastaticbreastcancer awareness. This blog post is the last content she wrote for us, a
Being invisible on a cancer ward…
Tassia Haines – METUPUK (Wales) member, patient advocate & fantastic artist. Back in February, I had to go into hospital after side effects from being on Trodelvy. I wanted
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS.
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted: Trastuzumab deruxtecan (Enhertu)